Mar 10, 2025 | Compliance, Consolidated Appropriations Act of 2021 (CAA), Regulatory, RxDC report
As you may recall, the Consolidated Appropriations Act of 2021 (CAA) requires group health plans to submit to the Centers for Medicare & Medicaid Services information about prescription drugs and health care spending. This data submission is called RxDC (for...
Feb 24, 2025 | Benefits preservation, Case Study, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Savings, Specialty Drugs
High-cost specialty drugs can make up more than 60% of a health plan’s pharmacy costs. MedBen Rx’s benefit preservation program is designed to make certain that members have continued access to medications while reducing specialty drug spend to the greatest...
Feb 11, 2025 | Benefits Advisory Conference, Caroline Fraker, Compliance, MedBen University, Pharmacies, Wellness
Over 70 guests from seven states attended the MedBen 2025 Benefits Advisory Conference on January 30. Featuring some of the most respected names in the industry, this invitation-only event provided brokers with an extensive look at the state of benefits...
Feb 10, 2025 | Cost Savings, Drug costs, Pharmacogenomics, Rx Costs, Savings
Now available through MedBen Rx, pharmacogenomic testing is transforming health care through safer and more effective personalized medicine. Determining how genes affect a person’s response to drugs not only improves patient outcomes, but it also helps control...
Jan 27, 2025 | Federal Trade Commission (FTC), MedBen Rx, News, Pharmacy Benefits Manager (PBM), Rx Costs, Specialty Drugs, Spread Pricing
Through specialty generic drug markups, three major pharmacy benefit managers (PBMs) earned a collective $7.3 billion above estimated acquisition costs over a five-year period, according to an interim report released by the Federal Trade Commission (FTC)....
